Lung cancer
Alesha A. Thai, Benjamin Solomon, Lecia Van Dam Sequist et al. · The Lancet · 2021
Cited by 2,576 works. doi:10.1016/s0140-6736(21)00312-3
Authors
References
- Cancer Incidence in Five Continents
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Global Cancer Statistics, 2002
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Cancer statistics, 2020
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma